Supplementary materials: Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA

<b>These are peer-reviewed supplementary materials for the article '</b><b>Health economic outcomes of switching </b><b>to alemtuzumab from other </b><b>disease-modifying therapies in people </b><b>with multiple sclerosis in the USA</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Supplementary Table 1: </b>Treatment duration of DMT used prior to switching to alemtuzumab (pre-index period). <b>Supplementary Table 2:</b> Average healthcare costs per person at index date (initiation of alemtuzumab).<b>Supplementary Figure 1:</b> Study design.<b>Aim:</b> Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs). <b>Patients &amp; methods: </b>Retrospective, observational study of IBM MarketScan claims database. PwMS previously treated with DMTs and initiating alemtuzumab (1 January 2013 to 31 December 2019) were identified. “Index” was date of alemtuzumab initiation (prescription filled). <b>Results:</b> The study cohort (n = 341) was primarily female (72%) with mean ± standard deviation) age 45.1 ± 9.5 years. At index, duration of MS was 5.3 ± 2.8 years. HCRU (inpatient/outpatient services), outpatient costs (including MS-specific MRI and emergency room visits) and annualized relapse rate significantly reduced over the 2 years following initiation of alemtuzumab. DMT costs reduced over the same period. <b>Conclusion:</b> Health economic and clinical benefits were seen following switching to alemtuzumab from other DMTs for treatment of MS, in this cohort from the USA.

本材料为发表于《Journal of Comparative Effectiveness Research》（《比较效果研究杂志》）的论文《美国多发性硬化患者从其他疾病修正疗法换用阿仑单抗的卫生经济学结局》的同行评议补充材料。

**补充表1**：换用阿仑单抗前使用的疾病修正疗法（disease-modifying therapies, DMT）治疗时长（索引前时期）。
**补充表2**：索引日（阿仑单抗起始给药日）的人均平均医疗费用。
**补充图1**：研究设计。

**研究目的**：阐述从其他疾病修正疗法（DMT）换用阿仑单抗的多发性硬化（multiple sclerosis, MS）患者（people with multiple sclerosis, pwMS）的人口学特征、临床特征、医疗资源利用（healthcare resource utilization, HCRU）及相关费用情况。

**研究对象与方法**：本研究为基于IBM MarketScan理赔数据库的回顾性观察性研究。纳入2013年1月1日至2019年12月31日期间曾接受疾病修正疗法治疗并起始使用阿仑单抗的多发性硬化患者。“索引日”定义为阿仑单抗处方配药的起始给药日期。

**研究结果**：本研究队列共纳入341例患者，其中女性占比72%，平均年龄为45.1±9.5岁（均值±标准差）。截至索引日，患者多发性硬化病程为5.3±2.8年。在起始使用阿仑单抗后的2年内，患者的医疗资源利用（住院/门诊服务）、门诊费用（包括多发性硬化特异性磁共振成像（magnetic resonance imaging, MRI）及急诊就诊费用）与年复发率均显著降低；同期疾病修正疗法相关费用亦有所下降。

**研究结论**：本项基于美国队列的研究显示，从其他疾病修正疗法换用阿仑单抗治疗多发性硬化后，可获得卫生经济学与临床获益。